{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:24:58Z","timestamp":1775805898539,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To describe the presence, type, and management of drug-drug interactions (DDIs) at prescription cannabidiol (CBD) therapy initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-center, retrospective study of patients prescribed CBD from a medical center\u2019s neurology clinic for seizure management from January 2019 through April 2020. Patients were excluded if they were enrolled in a CBD clinical trial or the insurance approval or medication fulfillment process was not completed by the center\u2019s specialty pharmacy. The primary outcomes were the numbers, types, and management of DDIs identified at the time of CBD prescribing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 136 patients included, 109 (80%) had a DDI identified at baseline. Of the 260 DDIs, 71% (n = 184) were pharmacodynamic and 29% (n = 76) were pharmacokinetic in nature. Management of the 260 DDIs detected included counseling only (89% [n = 232 interactions]), discontinuation of the interacting agent [9% (n = 22 interactions]), and dosage change for the interacting agent [2% (n = 6 interactions]). Clobazam was the most commonly identified interacting medication (n = 63, 24%), while valproic acid accounted for 10% (n = 26) of the DDIs. The population was predominantly white (n = 115, 85%), 18 years of age or younger (n = 92, 68%), and had an indication for prescription CBD treatment of Lennox-Gastaut syndrome (n = 117, 86%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study provides new information on the role that integrated specialty pharmacists can play in identifying and managing initial DDIs in patients starting prescription CBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac155","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T22:11:24Z","timestamp":1654726284000},"page":"1592-1598","source":"Crossref","is-referenced-by-count":9,"title":["Prescription cannabidiol for seizure disorder management: Initial drug-drug interaction management by specialty pharmacists"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-6225","authenticated-orcid":false,"given":"Holly","family":"Dial","sequence":"first","affiliation":[{"name":"Lipscomb University College of Pharmacy , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendi","family":"Owens","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8171-5766","authenticated-orcid":false,"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7090","authenticated-orcid":false,"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0691","authenticated-orcid":false,"given":"Autumn D","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2693-0372","authenticated-orcid":false,"given":"Nisha B","family":"Shah","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-7307","authenticated-orcid":false,"given":"Kayla","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center , Nashville, TN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"4","key":"2022090708590335500_CIT0001","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ncl.2016.06.015","article-title":"The epidemiology of global epilepsy","volume":"34","author":"Singh","year":"2016","journal-title":"Neurol Clin"},{"issue":"1","key":"2022090708590335500_CIT0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/CPJ.0b013e31823d07d1","article-title":"Treating patients with medically resistant epilepsy","volume":"1","author":"Krauss","year":"2011","journal-title":"Neurol Clin Pract"},{"key":"2022090708590335500_CIT0003","volume-title":"Package insert","author":"Epidiolex.","year":"2020"},{"issue":"10125","key":"2022090708590335500_CIT0004","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"2022090708590335500_CIT0005","first-page":"815","article-title":"Advancing patient care through specialty pharmacy services in an academic health system","volume":"23","author":"Bagwell","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"2022090708590335500_CIT0006","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2022090708590335500_CIT0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"issue":"21","key":"2022090708590335500_CIT0008","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"2022090708590335500_CIT0009","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"2022090708590335500_CIT0010","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"2022090708590335500_CIT0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/IPRP.S169282","article-title":"Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV\/HCV coinfection","volume":"7","author":"Olea","year":"2018","journal-title":"Integr Pharm Res Pract"},{"key":"2022090708590335500_CIT0012","doi-asserted-by":"crossref","first-page":"106235","DOI":"10.1016\/j.eplepsyres.2019.106235","article-title":"Initial assessment of an interprofessional team-delivered telehealth program for patients with epilepsy","volume":"158","author":"Axon","year":"2019","journal-title":"Epilepsy Res"},{"issue":"2","key":"2022090708590335500_CIT0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"2022090708590335500_CIT0014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac155\/44318438\/zxac155.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/18\/1592\/45685920\/zxac155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/18\/1592\/45685920\/zxac155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T08:59:57Z","timestamp":1662541197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/18\/1592\/6604466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":14,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,6,8]]},"published-print":{"date-parts":[[2022,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac155","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,15]]},"published":{"date-parts":[[2022,6,8]]}}}